Clinical Trials Logo
  1. Home
  2. Skin Irritation
  3. NCT03397862

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

Skin Irritation Clinical Trial

Official title:
A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

Clinical Trial Summary

A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)

Clinical Trial Description

This study is a multiple center, randomized, double-blind, vehicle-controlled, and multiple-dose study to assess skin irritation and skin sensitization in healthy subjects.

Subjects will be randomized prior to the first TDS application. The total duration of the study from Screening to Follow-up is approximately 95 days for subjects participating in the Induction Phase and the Challenge Phase of the study and potentially up to 156 days for subjects requiring to complete Re-Challenge Phase.

Skin irritation will be monitored by visual scoring scales. TDS adhesion will be assessed during TDS wear period. Safety will be monitored throughout the study by clinical and laboratory evaluations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03397862
Study type Interventional
Source Corium International Inc.
Contact
Status Completed
Phase Phase 1
Start date November 14, 2017
Completion date April 2, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01806831 - Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment N/A
Completed NCT02297841 - Repeated Insult Patch Test of Personal Lubricants N/A
Completed NCT02968446 - Effect of Vitamin D After Application With Valchlor Early Phase 1
Unknown status NCT01821274 - A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT01892657 - Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Phase 4
Withdrawn NCT02400320 - Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol Phase 4
Not yet recruiting NCT02645110 - Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations N/A
Completed NCT01887808 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30 N/A
Completed NCT01888887 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser N/A
Completed NCT01887860 - Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50 N/A
Completed NCT01892410 - Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash N/A
Completed NCT01892423 - Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion N/A